Abstract: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.

Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.

Abstract: The invention is based on feeding the closed bodies to be evaluated to a station for the application of high voltage for the formation of the arc across the inner space of the body and capturing the arc formed by means of a CCD camera which will compare, adjustably, the luminous intensity of the arc created within the body subjected to checking with a threshold value determining whether said luminous intensity is above or below said threshold, which will be the rejection threshold, rejecting the bodies which do not comply with the predetermined threshold value, separating them from the whole of the accepted bodies.

Abstract: The apparatus comprises an assembly of modules functionally interrelated with one another, and controlled by means of a central control unit in an embodiment of circular type in concentric rings of a reagent module and a rotatory carousel carrying the incubation reaction containers, with adjacent and external arrangement of a module for feeding the disposable reaction containers by means of detachable racks and a scanning device likewise concentric with the carousel, combining with a unit for feeding by pushing the reaction containers from the racks towards the grooves of the incubation carousel, and of two displacement arm devices.

Abstract: The stable thrombin composition comprises purified thrombin, human albumin and a neutral salt, the resulting product being stable when stored as a lyophilisate or frozen and is adjusted to a nominal strength of 500 IU of thrombin or more per ml of solution, the human albumin being in a concentration of over 0.05% (w/v) and preferably between 0.1% (w/v) and 1% (w/v).

Abstract: A main metering body has a coupling for a manual pump for filling the hardenable mass for vertebroplastia, permitting its independent filling and its subsequent introduction into the metering body, which is equipped with an end coupling for a high pressure flexible tubular member that can be coupled to the needle for introducing the hardenable mass, capable of being inserted on a long stylet for the initial puncture operation and a short stylet for the second and final puncture to the site where vertebroplastia is to be carried out.

Abstract: The apparatus comprises a transportable unit with a support base which is provided with wheels and which carries a source for the supply of CO2 under regulated pressure, having a support foot provided, at the top, with an articulated arm carrying a programming and control screen and means for receiving an exchangeable metering device capable of receiving the CO2 by way of ducts coming from the CO2 source and of metering it to an outlet for a catheter for administration to the patient, having motorised means capable of actuating the intake of CO2 into the metering device and of actuating the valves thereof in order to control the administration of the gas.

Abstract: The apparatus has two main regions of members the operation of which is controlled separately, the first region, to which the user has interactive access, permitting loading of the samples, controls, calibrators, diluents and other equipment for performing the sampling and dilutions and receiving the plate on which the tests are performed, and the second region, to which the user has occasional access, comprising stations dedicated to the rest of the process including incubation, washing, reading, and others, the second region being able to hold several plates at different stages of the process, the apparatus having means for automated movement along three coordinate axes X, Y, Z in order to transport the reagents and the plates in order to complete the process, enabling several tests to be performed at the same time on a set of samples in one or several plates, and enabling new series of tasks with the same or different sets of tests and with the same or different sets of samples to be started when the previ

Abstract: A universal apparatus for clinical analysis is provided comprising a base-board having three main levels. The first level holds a terminal for containers of reagents and samples and includes a device for cyclically vibrating individual vials. External graphic marks on vials and bottles and the internal characteristics of the same, such as the level of contents can be read. The second level of the base-board includes a thermostatic block which is provided with a number of grooves which can receive either disposable strips of small analytical containers or analytical cards. An agglutination reader is also provided. The third level carries a centrifuge which receives either strips or cards from a collection head having a clamp for collecting, conveying and placing in position the strips and cards; the head also including a pipetting needle.

Abstract: An efficient industrial method, by incubation at extreme (alkaline) pH in a stabilized medium, of inactivating viruses in general (with or without a lipid envelope) in media containing proteins for therapeutic use, without denaturing or significant loss of biological activity.

Abstract: There is described a therapeutic human albumin having a very low capacity for the absorption of aluminium, during storage in a glass receptacle, wherein the final composition of the albumin solution adjusted to be stable and isotonic at a concentration of 5, 20 or 25% of protein in an aqueous medium, preferably, or to any other therapeutic concentration acceptable for intravenous administration, has a citrate content in the final albumin composition equal to or less than 0.5 mM (millimolar) and, preferably, less than 0.037 mM (millimolar).

Abstract: The present invention provides a device for carrying out erythrocytic reactions, wherein the device includes a molded plate having multiple individual reaction compartments, each formed by an upper and lower chamber. The upper chamber is adapted to receive liquid for the first phase of the erythrocytic reaction which consists of dispensing reagents and samples, and the lower chamber contains a separating medium and reagents for the second phase of the reaction, wherein one or more products of the first phase are contacted with the contents of the lower chamber. The upper chamber communicates with the lower chamber through a narrow gap having a controlled width, such that the meniscus formed by surface tension prevents passage of the liquid in the upper chamber to the lower chamber, wherein centrifugation triggers the passage of liquid from one chamber to another.